UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $95.88 Million Position in Twist Bioscience Corporation $TWST

Key Points

• UBS Asset Management increased its stake in Twist Bioscience Corporation by 186.1% in the first quarter, owning 2,442,262 shares worth approximately $95.9 million.
• Research analysts have a consensus rating of "Moderate Buy" for TWST stock, with an average target price of $49.40, showing strong investor interest.
• Twist Bioscience's stock price has fluctuated between a 12-month low of $24.07 and a high of $55.33, indicating volatility in the market.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 186.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,442,262 shares of the company's stock after purchasing an additional 1,588,587 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 4.08% of Twist Bioscience worth $95,883,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. GAMMA Investing LLC increased its position in shares of Twist Bioscience by 68.1% in the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after acquiring an additional 303 shares during the last quarter. Versant Capital Management Inc increased its position in shares of Twist Bioscience by 547.2% in the first quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after acquiring an additional 580 shares during the last quarter. Knights of Columbus Asset Advisors LLC increased its position in shares of Twist Bioscience by 2.7% in the first quarter. Knights of Columbus Asset Advisors LLC now owns 23,178 shares of the company's stock valued at $910,000 after acquiring an additional 612 shares during the last quarter. Allianz Asset Management GmbH increased its position in shares of Twist Bioscience by 6.3% in the first quarter. Allianz Asset Management GmbH now owns 17,000 shares of the company's stock valued at $667,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Farther Finance Advisors LLC increased its position in shares of Twist Bioscience by 18.5% in the first quarter. Farther Finance Advisors LLC now owns 6,435 shares of the company's stock valued at $251,000 after acquiring an additional 1,006 shares during the last quarter.

Insider Activity at Twist Bioscience

In other news, CFO Adam Laponis sold 2,449 shares of the company's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $38.15, for a total value of $93,429.35. Following the transaction, the chief financial officer owned 103,569 shares of the company's stock, valued at approximately $3,951,157.35. This represents a 2.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Emily M. Leproust sold 2,265 shares of the company's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $25.76, for a total value of $58,346.40. Following the completion of the transaction, the chief executive officer directly owned 634,740 shares in the company, valued at $16,350,902.40. The trade was a 0.36% decrease in their position. The disclosure for this sale can be found here. Insiders sold 9,005 shares of company stock worth $290,540 in the last ninety days. 3.01% of the stock is owned by company insiders.

Twist Bioscience Stock Performance

NASDAQ TWST traded up $0.98 during trading on Thursday, reaching $27.95. 1,631,361 shares of the company's stock were exchanged, compared to its average volume of 1,381,888. The business has a 50 day moving average price of $29.67 and a 200-day moving average price of $33.93. The stock has a market capitalization of $1.69 billion, a P/E ratio of -19.28 and a beta of 2.31. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.90 and a quick ratio of 3.60. Twist Bioscience Corporation has a fifty-two week low of $24.07 and a fifty-two week high of $55.33.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.07. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%.The company had revenue of $96.06 million during the quarter, compared to analysts' expectations of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on TWST. Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 4th. Evercore ISI set a $46.00 target price on Twist Bioscience in a research report on Monday, August 4th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Twist Bioscience currently has an average rating of "Moderate Buy" and a consensus target price of $49.40.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.